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Abstract
Aims/hypothesis Current clinical guidelines for childhood-onset monogenic diabetes outside infancy are mainly focused on
identifying and testing for dominantly inherited, predominantly MODY genes. There are no systematic studies of the recessively
inherited causes of monogenic diabetes that are likely to be more common in populations with high rates of consanguinity. We
aimed to determine the contribution of recessive causes of monogenic diabetes in paediatric diabetes clinics and to identify
clinical criteria by which to select individuals for recessive monogenic diabetes testing.
Methods We conducted a cross-sectional study of 1093 children from seven paediatric diabetes clinics across Turkey (a population
with high rates of consanguinity).We undertook genetic testing of 50 known dominant and recessive causes of monogenic diabetes for
236 children at low risk of type 1 diabetes. As a comparison, we used monogenic diabetes cases fromUK paediatric diabetes clinics (a
population with low rates of consanguinity).
Results Thirty-four children in the Turkish cohort had monogenic diabetes, equating to a minimal prevalence of 3.1%, similar to
that in the UK cohort (p = 0.40). Forty-one per cent (14/34) had autosomal recessive causes in contrast to 1.6% (2/122) in the UK
monogenic diabetes cohort (p < 0.0001). All conventional criteria for identifying monogenic diabetes (parental diabetes, not
requiring insulin treatment, HbA1c ≤ 58 mmol/mol [≤7.5%] and a composite clinical probability of MODY >10%) assisted the
identification of the dominant (all p ≤ 0.0003) but not recessive cases (all p ≥ 0.2) in Turkey. The presence of certain non-
autoimmune extra-pancreatic features greatly assisted the identification of recessive (p < 0.0001, OR 66.9) but not dominant cases.
Conclusions/interpretation Recessively inherited mutations are a common cause of monogenic diabetes in populations with high
rates of consanguinity. Present MODY-focused genetic testing strategies do not identify affected individuals. To detect all cases
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of monogenic paediatric diabetes, it is crucial that recessive genes are included in genetic panels and that children are selected for
testing if they have certain non-autoimmune extra-pancreatic features in addition to current criteria.
Keywords Diabetes syndrome . MODY . Monogenic diabetes . Recessive monogenic diabetes . Syndromic diabetes . Type 1
diabetes . Type 1 diabetes genetic risk score
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Introduction
Research into childhood-onset monogenic diabetes outside the
neonatal period has focused on dominantly inherited genes,
especially MODY genes (HNF1A, HNF4A, GCK). Clinical
studies of MODY and other dominantly inherited monogenic
diabetes genes in children [1] have influenced clinical practice
and international guidelines towards patient selection criteria
for identifying dominantly inherited causes [2].
Mutations in recessively inherited genes are an important
cause of monogenic diabetes outside infancy. However, there
have been no systematic studies of recessive monogenic
diabetes genes in childhood-onset diabetes in populations with
high rates of consanguinity. If these genes are common in
certain populations, such studies are needed to improve
patient selection criteria, gene panels and clinical guidelines
for childhood-onset diabetes [1, 2].
In this study, we undertook systematic testing for dominant
and recessive monogenic diabetes genes in paediatric diabetes
clinic attendees in Turkey (a population with high rate of
consanguinity [~20%] [3]) and the UK (a population with
low rate of consanguinity [<1%] [4]). We assessed the contri-
bution of recessively inherited mutations to monogenic diabe-
tes in childhood-onset diabetes and identified a new clinical
criterion to use in routine clinical practice to select individuals
for recessive monogenic diabetes genetic testing.
Methods
Study population
We conducted a cross-sectional study of 1093 children attend-
ing paediatric diabetes clinics in seven hospitals across
Diabetologia
Turkey, recruited from April 2016 toMay 2017 (ESM Fig. 1).
Individualswith diabetes onset between 6months and 20 years
of age were eligible for the study. Baseline HbA1c, C-peptide
and islet autoantibody status were recorded during routine
clinical care. The presence of non-autoimmune extra-pancre-
atic features (i.e. in addition to diabetes), such as deafness,
developmental delay or anaemia, was recorded.
We collected saliva (1 ml) from which DNA was extracted
at LGC genomics (Hoddesdon, UK). The characteristics of the
cohort are provided in ESM Table 1. The self-reported rate of
parental consanguinity (second cousins or closer relatives)
was 20%. The sample size calculation is provided in ESM
Methods. The study was approved by the Kocaeli University
ethics committee (reference KOU KAEK 2016/01) and was
conducted in accordance with the Declaration of Helsinki. All
participants or their parents gave informed consent.
For a comparison population with a low rate of consan-
guinity, we included two cohorts of children with monogenic
diabetes from the UK (all screened using the same compre-
hensive genetic testing as the current study): one from our
previous systematic study in the same setting (n = 20) [5]
and one comprising routine UK diagnostic referrals to our
Exeter genetics laboratory with the same age at diagnosis
(0.5–20 years, n = 102).
Genetic data
Type 1 diabetes genetic risk scoreWeused 30 type 1 diabetes-
associated SNPs to generate a weighted type 1 diabetes genet-
ic risk score (T1D-GRS), as previously described [6] (ESM
Methods, ESM Table 2). T1D-GRS centiles were derived
from 1963 gold-standard European type 1 diabetes patients
from the Wellcome Trust Case Control Consortium
(WTCCC) [7]. The T1D-GRS of the 472 Turkish children
from our cohort with definite type 1 diabetes (clinically
diagnosed, insulin treated, islet autoantibody-positive) had a
similar median and distribution to those of the 1963 European
children (median [IQR] 0.279 [0.260–0.298] vs 0.280 [0.262–
0.298], Mann–Whitney U test p = 0.48, two-sample
Kolmogorov–Smirnov test p = 0.37) (ESM Fig. 2). These
data support our use of T1D-GRS centiles from the
European cohort to categorise Turkish children in the previ-
ously described low, moderate and high type 1 diabetes genet-
ic risk groups [6, 8, 9]. T1D-GRSwas defined as follows: low,
GRS <0.234 (<fifth centile of the WTCCC cohort); moderate,
GRS 0.234–0.280 (fifth to 50th centile of the WTCCC
cohort); and high, GRS >0.280 (>50th centile of the
WTCCC cohort).
Genetic testing for monogenic diabetes Based on our previ-
ous work [6, 9], we used a combination of T1D-GRS and islet
autoantibody status to select 236/1093 children with high to
moderate likelihood of monogenic diabetes (i.e. low/moderate
risk of type 1 diabetes) for genetic testing (ESM Fig. 1): 111
children with low T1D-GRS irrespective of islet autoantibody
status and 125 islet-autoantibody-negative children with a
moderate T1D-GRS (ESM Fig. 1). Genetic testing was not
carried out for 857 individuals with a low likelihood of mono-
genic diabetes (high T1D-GRS [n = 516], moderate T1D-
GRS and either islet autoantibody-positive [n = 208] or miss-
ing autoantibody status [n = 133] [ESMFig. 1]). This allowed
us to select individuals for genetic testing independent of the
clinical phenotype with high tomoderate probability of mono-
genic diabetes. We used targeted next generation sequencing
to analyse all known dominant and recessive genes causing
monogenic diabetes (n = 50) (ESM Methods and ESM
Table 3).
Statistical analysis
Data were analysed using STATA16 (StataCorp, USA). The
Mann–Whitney U test and the Fisher Exact test were used to
compare continuous and categorical variables, respectively.
The distribution of T1D-GRS between groups was compared
using a two-sample Kolmogorov–Smirnov test. We used the
exact binomial CI (Clopper–Pearson) method to calculate a
95% CI for the proportion. The prevalence of monogenic
diabetes was compared between the study cohorts using the
two-sample test for equality of proportions. We assessed the
strength of any association between a given clinical feature
and the presence of monogenic diabetes by calculating the
OR, its exact 95% CI and two-tailed Fisher’s exact p value.
WHO child growth BMI centiles were generated using the
Zanthro package [10], and the clinical probability of MODY
was determined using our validated statistical model [11].
Results
Recessive monogenic diabetes causes
Genetic analysis identified 34 individuals with monogenic
diabetes in the Turkish cohort, equating to a minimum preva-
lence of 3.1% (34/1093; 95% CI 2.2, 4.3) (Fig. 1a and ESM
Table 4), similar to that in the UK cohorts (2.5% [95% CI 1.5,
3.8], p = 0.40) [5], although genetic causes differedmarkedly.
Autosomal dominant causes (monoallelic pathogenic vari-
ants) were less common in the Turkish cohort than in the UK
cohorts (56% vs 100% [systematic study in UK paediatric
clinic, p = 0.64] and 96% [routine UK referral cohort, p =
1 × 10−7]). Autosomal recessive causes (biallelic pathogenic
variants) accounted for 14 Turkish individuals (41%) but were
rare in the UK: 0/20 in systematic study, p = 7 × 10−4 [5] and
2/102 in routine UK referrals, p = 2 × 10−8 (Fig. 1b and ESM
Tables 5, 6).
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Performance of selection criteria commonly used for
genetic testing
The clinical characteristics of the Turkish children differed for
those with dominant vs recessive causes of type 1 diabetes and
when comparing these children with the remainder of the
study population (ESM Table 7). Similar to the UK popula-
tion, non-insulin treatment, a parent with diabetes, HbA1c ≤
58 mmol/mol (7.5%) and a composite clinical probability of
MODY ≥10% were useful in identifying autosomal dominant
diabetes in the Turkish cohort (OR 105.1, 6.2, 10.3 and 38,
respectively, all p ≤ 0.0003) (Fig. 2 and ESM Table 8).
However, none of these criteria identified autosomal recessive
diabetes (all p ≥ 0.2).
New criteria for selecting individuals for recessive
monogenic diabetes testing
The presence of certain non-autoimmune extra-pancreatic
features markedly improved the identification of monogenic
diabetes with autosomal recessive cause when compared with
the rest of the cohort (OR 66.9 [95% CI 16.8, 379.1], p = 6×
10−12) (Fig. 2 and ESM Table 8). Eighteen discrete non-




















































































Turkey, n=34 UK, n=20 UK, n=102
Fig. 1 Recessive and dominant
inherited causes of monogenic
diabetes in the Turkish and UK
populations. (a) Bar chart
showing the number of
individuals with monogenic
diabetes by gene symbol and
mode of inheritance (n = 34)
identified in Turkish paediatric
clinics (age at diagnosis 0.5–
20 years). All monoallelic
variants were included under
autosomal dominant inheritance,




(b) Comparison of the mode of
inheritance of monogenic
diabetes in individuals identified
from the current study in Turkey
(a country with ~20%
consanguinity) and the UK (a
country with <1%
consanguinity). Data from the UK
are from individuals with
monogenic diabetes identified in
our previous systematic study in
the same setting (paediatric
diabetes clinic, n = 20/808) (11)
as well as cases identified from
routine diagnostic referrals
diagnosed between 0.5 and
20 years (n = 102). All cases
were identified by the same
comprehensive genetic testing of
all known autosomal dominant
and recessive causes of
monogenic diabetes as the current
study. ***p = 0.0005 for the
current study vs previous
systematic study from the UK;
†††p = 1 × 10−8 for the current
study vs routine diagnostic
referral from the UK
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individuals with monogenic diabetes (ESM Table 9); deaf-
ness, anaemia and developmental delay were seen in 9/14
autosomal recessive cases (ESM Table 4). Consanguinity of
parents also pointed towards autosomal recessive diabetes to a
lesser degree (OR 4 [95% CI 1.2, 13.5], p = 0.01). However,
neither criteria identified autosomal dominant diabetes (all p
> 0.2) (Fig. 2 and ESM Table 8).
Discussion
We show that mutations in recessive genes are major contrib-
utors to childhood-onset monogenic diabetes in a population
with a high rate of consanguinity. Comprehensive genetic
testing (of both dominant and recessive genes) shows for the
first time that despite having a similar overall prevalence in
Turkish and the UK populations, mutations in recessive
monogenic diabetes genes were 40-fold more common in
Turkey and accounted for nearly half of the cases. Although
this was expected due to the high rate of consanguinity, the
extent to which recessive aetiology contributes overall is not
known. Previous studies in this population mainly focused on
dominant genes [12–15], and currently available gene panel
tests for monogenic diabetes lack recessive genes (ESM
Table 10). Of the 34 gene panels for MODY/monogenic
diabetes listed in the NCBI Gene Testing Registry, only six
panels and one panel included WFS1 and SLC19A2, respec-
tively (the two commonest causes in our Turkish cohort)
(ESM Table 10).
Genetic testing independent of clinical features showed that
current criteria (derived predominantly from studies of
MODY genes in European ancestry populations) were still
useful for identifying MODY in Turkish children, as previ-
ously reported [12, 14, 15]. However, these criteria did not
identify recessive cases. We show that the presence of certain
non-autoimmune extra-pancreatic features is highly sugges-
tive of autosomal recessive causes (OR 66.9). It is known that
most recessive genetic subtypes have additional features, but
genetic testing is often restricted to individuals with features
suggestive of the syndrome. In our study, only 2/19 individ-
uals were clinically suspected of having a recessive cause (one
WFS1 and one SLC19A2), whereas the rest had atypical
features (ESM Table 4). These data suggest that the presence
of additional non-autoimmune features would be a useful
addition to current criteria for selecting individuals for mono-
genic diabetes genetic testing. This simple recommendation is
easy to implement and should be incorporated into guidelines
worldwide. This should be followed by urgent improvement
of current gene panels, which lack recessive genes.
We strongly recommend the inclusion of recessive genes in
the monogenic diabetes panel, even in countries with low rates
of consanguinity. It is not practical to have different gene
panels for monogenic diabetes within a single country. It is
sensible that all patients are tested for recessive causes and this
would avoid any hesitancy that healthcare professionals in
countries with low rates of consanguinity might have in
enquiring about consanguinity of parents. There is a small
additional cost of adding the recessive genes with next gener-



















New criteria for selecting patients for recessive
monogenic diabetes genetic testing
Classical criteria for selecting patients for
monogenic diabetes genetic testing
Fig. 2 Performance of selection
criteria for identifying monogenic
diabetes in Turkish paediatric
diabetes clinics. OR and 95% CI





A limitation of our study is that we did not genetically test
children at high diabetes genetic risk who were islet autoanti-
body negative. However, we expect that testing of these chil-
dren would identify only one or two additional cases of mono-
genic diabetes. Since we did not select children based on clin-
ical phenotype, these additional cases would not alter the
proportions of recessive and dominant cases and thus would
not change the overall conclusion of the study. However, this
additional testing may result in a slightly higher prevalence of
monogenic diabetes (3.3% instead of the present minimum
prevalence of 3.1%).
In conclusion, mutations in recessive monogenic diabetes
genes are an important contribution to childhood-onset mono-
genic diabetes outside infancy in populations with high rates
of consanguinity. Our results highlight the need for modifying
patient selection criteria for monogenic diabetes genetic test-
ing and suggest the urgent need to include recessive aetiol-
ogies in the current diagnostic gene panels to allow accurate
testing of diverse populations.
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